Antifungal activity of the new azole UK-109, 496 (voriconazole)

Mycoses, Supplement

Volumn 42, Issue 2, 1999, Pages 83-86

  Kappe, Reinhard ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Hygiene Institut   (Germany)

Author keywords

Antifungal activity; Azole antifungal; Triazole; Voriconazole

Indexed keywords

FLUCONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; CONFERENCE PAPER; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SENSITIVITY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; VISUAL DISORDER;

AJELLOMYCES CAPSULATUS; AJELLOMYCES DERMATITIDIS; ANIMALIA; ARTHRODERMATACEAE; ASPERGILLUS; BLASTOMYCES; BLASTOMYCES DERMATITIDIS; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; COCCIDIOIDES IMMITIS; CRYTOCOCCUS; CRYTOCOCCUS NEOFORMANS; FUNGI; FUSARIUM; HISTOPLASMA CAPSULATUM; ISSATCHENKIA ORIENTALIS; PARACOCCIDIOIDES BRASILIENSIS; PENICILLIUM MARNEFFEI; PSEUDALLESCHERIA BOYDII; SPOROTHRIX SCHENCKII; ZYGOMYCETES;

EID: 0033501998     PISSN: 09437312     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1439-0507.1999.tb00019.x     Document Type: Conference Paper

References (25)

1. Abraham, O. C., Manavathu, E. K., Cutright, J. L. & Chandrasekar, P. H. (1999) In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B. Diagn. Microbiol. Infect. Dis. 33, 7-11.
2. Cuenca Estrella, M., Rodriguez Tudela, J. L., Mellado, E., Martinez Suarez, J. V. & Monzon, A. (1998) Comparison of the in vitro activity of voriconazole (UK 109, 496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J. Antimicrob. Agents Chemother. 42, 531-533.
3. Manavathu, E. K., Cutright, J. L. & Chandrasekar, P. H. (1998) Organism-dependent fungicidal activities of azoles. J. Antimicrob. Agents Chemother. 42, 3018-3021.
4. Marco, F., Pfaller, M. A., Messer, S. A. & Jones, R. N. (1998) Antifungal activity of a new triazole, voriconazole (UK 109, 496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi. Med. Mycol. 36, 133-436.
5. McGinnis, M. R., Pasarell, L., Sutton, D. A., Fothergill, A. W., Cooper Jr, G. R. & Rinaldi, M. G. (1998) In vitro activity of voriconazole against selected fungi. Med. Mycol. 36, 239-242.
6. Verweij, P. E., Mensink, M., Rijs, A. J., Donnelly, J. P., Meis, J. F. & Denning, D. W. (1998) In vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates. J. Antimicrob. Agents Chemother. 42, 389-392.
7. Wildfeuer, A., Seidl, H. P., Paule, I. & Haberreiter, A. (1998) In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin in B and griseofulvin. Mycoses. 41, 309-319.
8. Sutton, D. A., Sanche, S. E., Revankar, S. G., Fothergill, A. W. & Rinaldi, M. G. (1999) In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 37, 2343-2345.
9. Verweij, P. E., van den Bergh, M. F., Rath, P. M., de Pauw, B. E., Voss, A. & Meis, J. F. (1999) Invasive aspergillosis caused by Aspergillus ustus: case report and review. J. Clin. Microbiol. 37, 1606-1609.
10. Clancy, C. J. & Nguyen, M. H. (1998) In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17, 573-575.
11. Jabado, N., Casanova, J. L., Haddad, E., Dulieu, F., Fournet, J. C., Dupont, B., Fischer, A., Hennequin, C. & Blanche, S. (1998) Invasive pulmonary infection due to Scedosporium apiospermum in two children with chronic granulomatous disease. Clin. Infect. Dis. 27, 1437-1441.
12. Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E. & Hajjeh, R. A. (1998) In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS 207147, Sch 56592, and voriconazole. J. Antimicrob. Agents Chemother. 42, 3242-3244.
13. Pfaller, M. A., Messer, S. A., Gee, S., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C. & Soll, D. R. (1999) In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. J. Clin. Microbiol. 37, 870-872.
14. Cuenca Estrella, M., Diaz Guerra, T. M., Mellado, E., Monzon, A. & Rodriguez Tudela, J. L. (1999) Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur. J. Clin. Microbiol. Infect. Dis. 18, 432-435.
15. Ruhnke, M., Schmidt-Westhausen, A. & Trautmann, M. (1997) In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. J. Antimicrob. Agents Chemother. 41, 575-577.
16. Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K. & Ghannoum, M. A. (1999) In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neuformans from the United States and Africa. J. Antimicrob. Agents Chemother. 43, 169-171.
17. Mondom, P., Petter, R., Amalfitano, G., Luzzati, R., Concia, E., Polacheck, I. & Kwon Chung, K. J. (1999) Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. J. Antimicrob. Agents Chemother. 43, 1856-1861.
18. Hoban, D. J., Zhanel, G. G. & Karlowsky, J. A. (1999) In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. J. Antimicrob. Agents Chemother. 43, 1463-1461.
19. Johnson, E. M., Szekely, A. & Warnock, D. W. (1998) In vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J. Antimicrob. Agents Chemother. 42, 741-745.
20. Martin, M. V., Yates, J. & Hitchcock, C. A. (1997) Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. J. Antimicrob. Agents Chemother. 41, 13-16.
21. Murphy, M., Bernard, E. M., Ishimaru, T. & Armstrong, D. (1997) Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. J. Antimicrob. Agents Chemother. 41, 696-698.
22. Ghannoum, M. A., Okogbule Wonodi, I., Bhat, N. & Sanati, H. (1999) Antifungal activity of voriconazole (UK 109, 196), fluconazole and amphotericin B against hematogenous Candida krusei infection in neutropenic guinea pig model. J. Chemother. 11, 34-39.
23. Lozano Chiu, M., Arikan, S., Paetznick, V. L., Anaissic, E. J. & Rex, J. H. (1999) Optimizing voriconazole susceptibility testing of Candida: effects of incubation time, endpoint rule, species of Candida, and level of fluconazole susceptibility. J. Clin. Microbiol. 37, 2755-2759.
24. Kauffman, C. A. & Zarins, L. T. (1999) Colorimetric method for susceptibility testing of voriconazole and other triazoles against Candida species. Mycoses 42, 539-542.
25. Fegeler, W., Bille, J., Dupont, B., Edebo, L. B., Ellis, D. H., Kappe, R., Makristathis, A., Meis, J. F. G. M., Mittermayer, H., Ritzler, M., Schär, G., Schmalreck, A.-F., Viviani, M. A. & Willinger, B. (1999) Distribution of yeast species in clinical routine diagnostic specimen and their susceptibility against fluconazole, voriconazole and flucytosine. P53, 5th Congress, European Confederation of Medical Mycology (ECMM), and 33. Wissenschaftl Tagung Deutschspr Mykolog Ges, Dresden. Mycoses 42, 174-175.